Arecor's Sarah Howell talks to Proactive London after being awarded a £2.8 million grant from Innovate UK to support the Phase II development of AT247, an ultra-rapid acting insulin product candidate. Howell explains how this treatment is based on Arecor’s proprietary Arestat technology platform.
AT247, the lead product from their pipeline of next generation rapid insulins is focused on transforming the lives of people living with Type 1 diabetes through its potential to enable greater glucose control.